166 related articles for article (PubMed ID: 30725589)
1. Promising Anti-Hepatitis C Virus Compounds from Natural Resources.
Wahyuni TS; Utsubo CA; Hotta H
Nat Prod Commun; 2016 Aug; 11(8):1193-1200. PubMed ID: 30725589
[TBL] [Abstract][Full Text] [Related]
2. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.
Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT
Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176
[TBL] [Abstract][Full Text] [Related]
3. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
4. Review on chemogenomic approaches towards hepatitis C viral targets.
Venkatesan A; Prabhu Dass J F
J Cell Biochem; 2019 Aug; 120(8):12167-12181. PubMed ID: 30887580
[TBL] [Abstract][Full Text] [Related]
5. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.
Casey JL; Feld JJ; MacParland SA
Cells; 2019 Apr; 8(4):. PubMed ID: 30959825
[TBL] [Abstract][Full Text] [Related]
6. Anti-hepatitis C virus activity and synergistic effect of Nymphaea alba extracts and bioactive constituents in liver infected cells.
Rehman S; Ashfaq UA; Ijaz B; Riazuddin S
Microb Pathog; 2018 Aug; 121():198-209. PubMed ID: 29775725
[TBL] [Abstract][Full Text] [Related]
7. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.
Das D; Pandya M
Mini Rev Med Chem; 2018; 18(7):584-596. PubMed ID: 28901852
[TBL] [Abstract][Full Text] [Related]
8. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
9. [Progress in Examination and Treatment of Hepatitis C Virus].
Suda G; Sakamoto N
Rinsho Byori; 2015 Jun; 63(6):762-7. PubMed ID: 26548242
[TBL] [Abstract][Full Text] [Related]
10. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
[TBL] [Abstract][Full Text] [Related]
11. Plant-derived antivirals against hepatitis c virus infection.
Jardim ACG; Shimizu JF; Rahal P; Harris M
Virol J; 2018 Feb; 15(1):34. PubMed ID: 29439720
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of fluorene compounds inhibiting HCV variants.
Kim HS; You Y; Mun J; Gadhe CG; Moon H; Lee JS; Pae AN; Kohara M; Keum G; Kim BM; Jang SK
Antiviral Res; 2020 Feb; 174():104678. PubMed ID: 31862501
[TBL] [Abstract][Full Text] [Related]
13. Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.
Nguyen BN; Okuno Y; Ajiro M; Iida K; Denawa M; Yamamoto M; Sakamoto N; Kagechika H; Hagiwara M
J Med Virol; 2017 Jul; 89(7):1224-1234. PubMed ID: 27922182
[TBL] [Abstract][Full Text] [Related]
14. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
15. Direct-acting and host-targeting HCV inhibitors: current and future directions.
Chatel-Chaix L; Germain MA; Götte M; Lamarre D
Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
[TBL] [Abstract][Full Text] [Related]
16. Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
Ogata F; Kobayashi M; Akuta N; Osawa M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K; Kumada H
Oncology; 2017; 93(2):92-98. PubMed ID: 28448999
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus infection.
Manns MP; Buti M; Gane E; Pawlotsky JM; Razavi H; Terrault N; Younossi Z
Nat Rev Dis Primers; 2017 Mar; 3():17006. PubMed ID: 28252637
[TBL] [Abstract][Full Text] [Related]
18. SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
Li X; Han J; Lee HW; Yoon YS; Jin Y; Khadka DB; Yang S; Kim M; Cho WJ
Bioorg Med Chem; 2020 Oct; 28(19):115679. PubMed ID: 32912430
[TBL] [Abstract][Full Text] [Related]
19. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
[TBL] [Abstract][Full Text] [Related]
20. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
